• Rencofilstat–Ixazomib in Advanced Prostate Cancer

  2026-09-02

  A 2025 Biomedicines study shows that combining the pan-cyclophilin inhibitor rencofilstat with the proteasome inhibitor ixazomib intensifies proteotoxic stress and apoptotic death in advanced prostate cancer cells while sparing non-cancer cells. Its mechanistic contribution is the identification of altered XBP1s, PERK, cyclophilin, CD147, and ERK signaling as interconnected determinants of treatment response.

• Fenipentol: From Natural Product to Assay Design

  2026-09-01

  Fenipentol, also known as 1-Phenyl-1-pentanol, connects a Ligusticum chuanxiong natural-product signal with testable gastrointestinal, hepatobiliary, and cardiovascular hypotheses. This article focuses on evidence hierarchy, assay selection, and practical workflow decisions rather than repeating a conventional mechanism overview.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-09-01

  A scenario-driven guide to using HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody, SKU K1214, in immunofluorescence, flow cytometry, Western blotting, and tissue staining workflows. It explains how to improve detection of goat primary antibodies while separating fluorescence-based mechanistic readouts from direct cell-viability measurements.

• Persistent rDNA Damage and PML-Nucleolar Compartments

  2026-08-31

  Urbancokova, Hornofova and colleagues identify persistent ribosomal DNA damage as a specific trigger of PML-nucleolar associations, linking topological stress, RNA polymerase I inhibition, and incomplete homologous recombination. The study provides a useful framework for distinguishing transient genotoxic stress from lesions that reorganize nucleolar architecture and promote senescence.

• HRP Secondary Antibodies in Plastic Toxicology

  2026-08-31

  A translational perspective on how HRP-based immunodetection can strengthen mechanistic studies of microplastic- and nanoplastic-induced pulmonary fibrosis, with practical guidance for deploying goat primary antibodies across toxicology workflows.

• Microplastics, Nanoplastics, and Pulmonary Fibrosis

  2026-08-30

  A comparative study shows that polystyrene, polyethylene, and polypropylene microplastics and nanoplastics can promote fibrotic lung injury, with smaller particles and polystyrene producing the strongest effects. Its combined animal, epithelial-cell, and pathway-intervention design implicates dysregulated FXR–YAP1 signaling as a potential mechanism while highlighting important limits for translating exposure models to human risk.

• rTMS Activates GABAergic Cx3cl1-Cx3cr1 Signaling in AD

  2026-08-29

  This 2025 Cell Proliferation study links repetitive transcranial magnetic stimulation (rTMS) to cognitive recovery in 5xFAD mice through activation of GABAergic neurons and enhancement of the Cx3cl1-Cx3cr1 signaling axis. Single-cell transcriptomics and cellular analyses suggest that this pathway improves microglial phagocytosis, reduces amyloid plaque burden, and suppresses neuroinflammatory features.

• Dihydroartemisinin: Applied Research Workflows

  2026-08-28

  Build reproducible malaria, mTOR, and inflammation assays around a defined Dihydroartemisinin workflow rather than an undefined botanical preparation. This guide covers solvent handling, exposure design, reference-informed antiplasmodial assay choices, and troubleshooting for precipitation, light sensitivity, and pathway-level interpretation.

• Thrombin B Chain Fragment: Mechanism & Assays

  2026-08-28

  Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] is a defined 19-residue peptide fragment associated with the human F2 thrombin system. This article separates thrombin biology from the product’s fragment identity, summarizes assay-relevant specifications, and defines practical limits for coagulation and vascular research.

• CX-5461 in Cervical Cancer: Mitotic Catastrophe

  2026-08-27

  A 2026 Biochemical Pharmacology study shows that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by coupling DNA damage to abnormal mitotic entry and mitotic catastrophe. The study also reports enhanced cisplatin sensitivity, providing a mechanistic rationale for investigating Pol I inhibition in treatment-resistant cervical cancer models.

• DSS Models and the GPR35–KLF5 Repair Axis

  2026-08-27

  Dextran sulfate sodium salt (MW 35000-45000) is more than a routine colitis reagent: it is a controlled way to interrogate how epithelial injury becomes a repair decision. This thought-leadership guide connects DSS-based intestinal inflammation models with recent evidence on GPR35–KLF5 signaling, then translates that biology into practical study-design and translational strategy.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-08-26

  This study identifies Polo-like kinase 1 (Plk1)-dependent phosphorylation of p31comet at S102 as a brake on mitotic checkpoint complex disassembly. The work links a specific post-translational modification to control of the p31comet–TRIP13 pathway, explaining how cells may prevent premature checkpoint silencing during chromosome alignment.

• Purmorphamine: A Cross-Species Smo Assay Map

  2026-08-26

  Purmorphamine is a Smoothened agonist that connects Hedgehog pathway activation with osteogenic and sensory biology. This article translates Apis mellifera findings into a practical framework for interpreting pathway, receptor, and phenotype-level assays.

• Partial BACE Inhibition and Synaptic Transmission

  2026-08-25

  Satir et al. show that partial β-secretase inhibition can reduce amyloid β secretion by up to 50% without measurable loss of synaptic transmission in cultured primary rat neurons. The study defines an experimentally relevant exposure window and suggests that moderate, rather than near-complete, target suppression may be important when designing preventive Alzheimer’s disease interventions.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-25

  The 2025 reference study shows that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike-protein binding to host receptors, with especially strong effects observed for shorter N-terminal deletion products. Its antibody-based binding strategy provides a framework for examining how renin–angiotensin system peptides may influence viral receptor interactions, while also highlighting the need for cell-based and in vivo validation.

8497 records 1/567 page Next 12345 下5页 Last page